<DOC>
	<DOCNO>NCT02746042</DOCNO>
	<brief_summary>To assess efficacy herbal medicinal product Sinupret extract versus placebo treatment chronic rhinosinusitis ( CRS ) adult .</brief_summary>
	<brief_title>Sinupret Extract Coated Tablets Chronic Rhinosinusitis</brief_title>
	<detailed_description>The aim present double-blind , placebo-controlled , parallel-group , randomize , phase III clinical trial ass efficacy , safety , tolerability Sinupret extract ( 3 x 160 mg = 480 mg daily ) take 16-weeks compare placebo treatment chronic rhinosinusitis ( CRS ) adult . In addition , exploratory approach identify potential pharmacological mode action underlie expect treatment benefit , anti-inflammatory activity Sinupret extract assess subset CRS patient .</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<criteria>1 . Signed informed consent ( IC ) include data protection declaration 2 . Male female outpatient age ≥18 ≤75 year Women consider inclusion pregnant ( confirm urine pregnancy test V1 V2 ) , breastfeed , surgically sterile ( documented bilateral oophorectomy and/or hysterectomy ) menopause ensure ( least 12 month without menstrual bleeding ) . Women childbearing potential must use highly effective ( failure rate le 1 % per year , i.e . Pearl Index &lt; 1 ) method contraception 2 week prior trial inclusion screening/treatment period clinical trial ( e.g . vasectomized partner , sexual abstinence lifestyle female complete abstinence intercourse 2 week prior first dose trial medication least 72 hour treatment implant , injectables , combine oral contraceptive , hormonal intrauterine device ) . 3 . Diagnosis bilateral CRS without nasal polyp confirm : Nasal endoscopy screen phase confirm inflammation , mucopurulent discharge , and/or edema/mucosal obstruction primarily middle meatus without nasal polyp present At discretion investigator , result historic image diagnostic , i.e . computer tomography ( CT ) , digital volume tomography ( DVT ) , magnetic resonance tomography ( MRT ) ( screen old 24 month , take acute exacerbation ) , consider additionally confirmation bilateral involvement middle meatus paranasal sinuses without resolution symptom ( mucosal change within ostiomeatal complex and/or sinus ) 4 . Bilateral CRS characterize : Presence CRS symptom &gt; 52 week prior enrolment ( V1 ) document medical file patient Major Symptom Score ( MSS ) ≥10 V1 V2 assess investigator ( MSS INV ) , rhinorrhea ( anterior posterior ) pain ( facial pain headache ) least moderate intensity ( score ≥2 ) 1 . Sinus surgery within last 2 year ( solitary sinus puncture allow ) 2 . Inferior turbinate reduction ( surgery method ) within last 3 month 3 . Presence history uni bilateral nasal polyp 4 . Moderate severe comorbid asthma , include allergic asthma 5 . Cystic fibrosis 6 . Perennial ( e.g . patient clinical symptom allergic rhinitis house dust/mite antigen ) seasonal allergic rhinitis 7 . Rhinitis medicamentosa ( drug induce rhinitis ) 8 . Aspirinexacerbated respiratory disease ( aspirin sensitivity ) 9 . Dentogenic sinusitis otherwise unilateral sinusitis 10 . Presence anatomical deviation nasal septum significantly impair nasal paranasal ventilation/airflow 11 . Known hypersensitivity trial medication excipients 12 . Rare hereditary problem fructose intolerance , galactose intolerance , lactase deficiency , glucosegalactose malabsorption , sucrase isomaltase insufficiency 13 . Signs symptom acute bacterial sinusitis ( e.g . fever &gt; 38.5°C , orbital complication , severe unilateral frontal headache , toothache ) 14 . Treatment antihistamine within 4 week prior V1 15 . Treatment 23.5 % hypertonic saline solution within 2 week prior V1 16 . Treatment systemic nasal antibiotic corticosteroid within 4 week prior V1 17 . Treatment decongestant preparation ( αsympathomimetics ) , analgesic ( include systemic nonsteroidal inflammatory drug [ NSAIDs ] , include paracetamol ) , mucolytics/secretolytics , alternative medicine preparation treatment common coldlike symptom immunomodulating property within 7 day prior V1 18 . Peptic ulcer 19 . Gastritis 20 . Other disease within 5 year prior V1 , opinion investigator , disqualify patient trial enrolment ( e.g . liver kidney disease , severe somatopathic , neurological and/or psychiatric disease , history malignancy , alcohol drug abuse , immunodeficiency ) 21 . Parallel participation another clinical trial , participation different trial within less 6 week prior trial entry , previous randomization clinical trial 22 . Known , suspect unable comply clinical trial protocol ( CTP ) opinion investigator disqualifies patient trial enrolment ( e.g . permanent address , know noncompliant , present unstable psychiatric history ) 23 . Legal incapacity and/or circumstance render patient unable understand nature , scope , possible impact clinical trial 24 . Patients custody juridical official order 25 . Patients difficulty understand local language patient information ( PI ) give 26 . Patients member staff investigational site , staff sponsor involve CRO , investigator him/herself close relative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>chronic rhinosinusitis</keyword>
	<keyword>Sinupret extract</keyword>
	<keyword>herbal medicinal product</keyword>
</DOC>